NCT01801293View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

RSV Infection

Interventions

DRUG

GS-5806

Trial Locations (1)

53704

Investigational Site, Madison

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY